Research Hub

Veteran Restoration

Psilocybin-assisted therapy for combat trauma and treatment-resistant PTSD

22 U.S. military veterans die by suicide every day — driving urgency for alternative treatment research
Overview

Emerging clinical research on psilocybin as an intervention for military veterans experiencing treatment-resistant PTSD, moral injury, and suicidality — addressing the crisis of 22 veteran suicides per day.

Psilocybin for Combat Trauma and PTSD

Post-traumatic stress disorder affects an estimated 20% of veterans who served in Iraq and Afghanistan, and conventional treatments fail a significant proportion. SSRIs — the primary pharmacological intervention — achieve full remission in fewer than 30% of PTSD patients. Prolonged exposure therapy and EMDR show better results but are difficult to access and have high dropout rates. The human cost of this treatment gap is measured in veteran suicide rates that remain chronically elevated — roughly 20 per day in the United States.

Psilocybin offers a mechanistically distinct approach. PTSD is fundamentally a disorder of threat-response dysregulation, intrusive memory consolidation, and fear extinction failure. The amygdala is hyperactive; the prefrontal cortex's capacity to modulate fear responses is compromised; traumatic memories are encoded with excessive emotional valence that persists across decades. Conventional medications address surface symptoms. Psilocybin appears to target the underlying architecture.

The combination of Default Mode Network disruption, fear extinction facilitation (via 5-HT2A-mediated inhibition of amygdala threat circuitry), and enhanced neuroplasticity creates conditions in which traumatic memories can be reprocessed without triggering the full physiological threat response. Military veterans in early trials describe being able to examine traumatic experiences "from a distance" — emotionally present but not overwhelmed. Multiple clinical programs, including work by the Multidisciplinary Association for Psychedelic Studies (MAPS) and academic sites at NYU and Johns Hopkins, are now specifically studying veteran populations.

The moral dimension matters here. Veterans took psychic wounds in service to their communities. The obligation to provide them with the most effective available treatments — not the most politically comfortable — should be self-evident. The science articles in this collection build the case that psilocybin deserves serious consideration as part of that treatment landscape.

Articles in This Collection
Veterans and Psilocybin: The Neuroscience of Healing the Wounds of War
22 veterans die by suicide every day. Combat trauma damages four neural systems at once — amygdala,…
Psilocybin and Chronic Pain: The Neuroscience of Breaking the Pain Cycle
Chronic pain rewires the brain's default mode network in the same way addiction does — trapping millions in…
Psilocybin and Grief: The Neuroscience of Healing What Cannot Be Fixed
For 7 to 10 percent of bereaved individuals, grief does not end — it loops. A DMN prediction machine…
Psilocybin and PTSD: The Emerging Evidence
Post-traumatic stress disorder is not a memory problem — it is a fear extinction failure. The brain learned…
Psilocybin and Depression: What Phase 3 Clinical Trials Actually Show
The most rigorously controlled psychedelic trials in psychiatry history have produced results mainstream…
From Battlefield to Breakthrough: Psilocybin-Assisted Therapy for Veterans
22 veterans die by suicide every day. The current standard of care is failing them. Psilocybin-assisted…
Key Researchers
Matthew Johnson OOTW Research Desk

Browse All Research Hubs

◉ The OOTW Podcast

Hear the science, every day.

Every OOTW deep dive — each article narrated, and as a two-host conversation. Press play, or follow the show on your platform of choice.

▸ Follow the show →